The birth weight of macrosomia influence the accuracy of ultrasound estimation of fetal weight at term.

OBJECTIVE: To evaluate and analyze the accuracy of ultrasound estimation of the fetal weight of Macrosomia at term. METHOD: The instruments used were α6(Aloka; Japan) color Doppler ultrasound imagers, and vinno 80 (feieno; China) with a frequency of 3.5 MHz. The formula used to calculate the estimated fetal birth weight (EFW) was that proposed by Hadlock et al. (Hadlock 2). The biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC), and femur length (FL) measurements were performed strictly following the practice guidelines. Detailed measurement standards are shown in the figure and the table in the text. Macrosomia is typically defined as a birth weight above the 90th percentile for gestational age or >4000 g.Two indexes were used to calculate the error between EFW and birth weight (BW): Simple error (SE = BW - EFW); Absolute percentage error (APE, which reflects this percentage in absolute value, percentage error [PE = SE/BW] × 100). In order to better evaluate the measurement results, we made the following definitions: 1. When APE > 15%, the measurement deviation is significant. 2. The ratio of those cases with APE > 15% to the total number of cases measured by a sonographer was greater than 20%, indicating that the sonographer was prone to significant measurement deviation. RESULT: A total of 374 cases were analyzed. The mean maternal age was 31.48 (±15.93) years. Each pregnant woman carries only one fetus. The mean gestational age at delivery was 39.93 (±0.84) weeks. There were 245 male infants (65.5%), 129 female infants (34.5%), 214 cesarean section (57.2%), and 160 vaginal delivery (42.7%). 339 cases (90.64%) were estimated to be lower than the actual BW. The estimated weight was higher than the actual weight in 35 cases, accounting for 9.36%.The APE>15% in 56 cases, accounting for 14.97%. The accuracy of estimated fetal weight was closely related to the BW of the fetus and had no significant correlation with the seniority of the physician, the gender of the fetus, and the fetal position. CONCLUSION: Studies on macrosomia have shown that the BW of macrosomia tends to be underestimated, which is also reflected in the results of this study. The accuracy of estimated fetal weight still needs to be improved. Our study found that the accuracy of estimated fetal weight was closely related to the BW of the fetus and had no significant correlation with the seniority of the physician, the gender of the fetus, and the fetal position. The correlation between the section and calculation formula on the measurement accuracy needs to be studied. Through systematic data analysis, we can find the doctors whose measurements are relatively inaccurate in our department and carry out targeted quality control to improve the measurement accuracy.

Tanshinone I and Tanshinone IIA/B attenuate LPS-induced mastitis via regulating the NF-κB.

BACKGROUND: Mastitis is a common disease occurs in breast-feeding mothers, but published data are poor. This study aimed to study the effects of Tanshinones on treating mastitis. METHODS: Clinical trials performed in 58 breast-feeding mothers were carried out. B-ultrasound and blood test were used to measure the size of breast mass and the change of blood cell counts. BALB/c mice were injected with LPS and then treated by Tanshinone I or Tanshinone IIA/B. Myeloperoxidase (MPO) activity and the release of inflammatory cytokines were tested by MPO kit, RT-qPCR and ELISA. Mouse mammary epithelial cells (mMECs) were isolated and the effects of Tanshinones were measured by conducting CCK-8 assay, flow cytometry, RT-qPCR and ELISA. RESULTS: Patients treated by Cefprozil combined with Tanshinone got better outcomes than patients treated by Cefprozil alone. In animal trials, Tanshinone I and Tanshinone IIA/B significantly reduced MPO activity, and the levels of TNF-α, IL-1ß and IL-6 in serum and mammary gland tissues. In mMECs, Tanshinone I and Tanshinone IIA/B attenuated LPS-induced viability loss and apoptosis. And they effectively inhibited the release of TNF-α, IL-1ß and IL-6. Also, Tanshinone I and Tanshinone IIA/B significantly attenuated LPS-evoked NF-κB activation. CONCLUSION: Tanshinone I and Tanshinone IIA/B have potentials in treating mastitis. The beneficial effects might be through regulating NF-κB activation.